Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from th…

– Construction of a new buffer media station in Laupheim
– Largest investment in the German site; project duration of approx. three years
– Continuous modernization, automation, and digitalization of the site

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CD…

– Expanded service offering client ready at company’s site in Stevenage, UK
– Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral vectors

Rentschler Biopharma SE, a leading global contract development an…

– Largest expansion in company’s 150+-year history opens
– Major client project already underway; new clients actively being onboarded

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products…

– UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
– Highly experienced team ready to support ATMP innovators at all stages
– Offering comprehensive range of services from early process and analytical development through cGMP manufacturing for clinical t…

Rentschler Biopharma und Vetter, zwei weltweit operierende Contract Development und Manufacturing Organisationen (CDMO), präsentieren Xpert Alliance, eine gemeinsame Visualisierung ihrer strategischen Zusammenarbeit. Diese ist Ausdruck der gelebten und erfolgreichen Allianz, welche effektive Lösun…

- Manufacturing capacity for biopharmaceuticals is important benchmark for Germany as a biotechnology location, according to yesterday’s Biotech Report published by vfa bio and Boston Consulting Group
- Rentschler Biopharma expands production capacity with 2,000-liter bioreactor to address increasing…